- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
MRD negativity: considerations for older adults with multiple myeloma ; volume:13 ; number:1 ; day:8 ; month:11 ; year:2023 ; pages:1-3 ; date:12.2023
Blood cancer journal ; 13, Heft 1 (8.11.2023), 1-3, 12.2023
- Creator
-
Mian, Hira
Wildes, Tanya M.
Venner, Christopher P.
Fonseca, Rafael
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-023-00939-y
- URN
-
urn:nbn:de:101:1-2024012910344890387438
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mian, Hira
- Wildes, Tanya M.
- Venner, Christopher P.
- Fonseca, Rafael
- SpringerLink (Online service)
Other Objects (12)
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma
Herstellung von 50 Mio.-, 100 Mio.-, 500 Mio.-, 1 Mrd.-, 5 Mrd.-, 20 Mrd.-, 50 Mrd.-, 100 Mrd.-, 200 Mrd.-, 500 Mrd.-M-Scheinen, 1 Bill.-, 5 Bill.-, 20 Bill.-M-Scheinen
Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
WM: 10 MRD {EURO} BRASILIANISCHE BILDUNG: 4,5 MRD {EURO}
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Feminism, Negativity, Intersubjectivity
Ein 100-Mrd.-Mißverständnis
A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
Rethinking the Negativity Bias
Platonism, Alienation, and Negativity
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma
Herstellung von 50 Mio.-, 100 Mio.-, 500 Mio.-, 1 Mrd.-, 5 Mrd.-, 20 Mrd.-, 50 Mrd.-, 100 Mrd.-, 200 Mrd.-, 500 Mrd.-M-Scheinen, 1 Bill.-, 5 Bill.-, 20 Bill.-M-Scheinen
Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
WM: 10 MRD {EURO} BRASILIANISCHE BILDUNG: 4,5 MRD {EURO}
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Feminism, Negativity, Intersubjectivity
Ein 100-Mrd.-Mißverständnis
A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
Rethinking the Negativity Bias
Platonism, Alienation, and Negativity
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma
Herstellung von 50 Mio.-, 100 Mio.-, 500 Mio.-, 1 Mrd.-, 5 Mrd.-, 20 Mrd.-, 50 Mrd.-, 100 Mrd.-, 200 Mrd.-, 500 Mrd.-M-Scheinen, 1 Bill.-, 5 Bill.-, 20 Bill.-M-Scheinen
Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
WM: 10 MRD {EURO} BRASILIANISCHE BILDUNG: 4,5 MRD {EURO}
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Feminism, Negativity, Intersubjectivity
Ein 100-Mrd.-Mißverständnis
A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
Rethinking the Negativity Bias